METHODS OF SELF-ADMINISTRATION OF VANOXERINE FOR TERMINATING ACUTE EPISODES OF CARDIAC ARRHYTHMIA IN MAMMALS
Disclosed embodiments are related to methods of administration of vanoxerine wherein a patient, previously and successfully treated for cardiac arrhythmia with vanoxerine is prescribed a further dose for self-administration of a further dose of vanoxerine for treatment of a subsequent occurrence of cardiac arrhythmia.
1 . A method for administering vanoxerine to a patient for treatment of cardiac arrhythmia comprising: administering a first dose of vanoxerine; measuring the physiological concentration of vanoxerine; determining an effective second dose of vanoxerine based on the measured physiological concentration; providing an effective second dose to the patient; and instructing the patient to self-administer the second dose of vanoxerine upon the occurrence of an episode of cardiac arrhythmia.
2 . The method of claim 1 further comprising the step of comparing the measure dose of vanoxerine to a pre-determined target physiological concentration.
3 . The method of claim 2 wherein the pre-determined target physiological concentration is based on the plasma concentration.
4 . The method of claim 3 wherein the target physiological concentration is between 20 and 150 ng/ml at a time between 1 and 4 hours post administration.
5 . The method of claim 3 wherein the target physiological concentration is between 60 and 130 ng/ml at a time between 1 and 4 hours post administration.
6 . A method for modulating plasma level concentrations in a patient being treated for cardiac arrhythmia comprising: administering a first dose of vanoxerine; measuring the plasma level concentration of vanoxerine in the patient; comparing the measured dose of vanoxerine to a pre-determined target plasma level; providing the patient with a further effective dose of vanoxerine; and instructing the patient to administer the further dose of vanoxerine upon re-occurrence of cardiac arrhythmia.
7 . The method of claim 6 wherein the target plasma concentration is between 40 and 150 ng/ml.
8 . The method of claim 6 wherein the target plasma level concentration is between 60 and 120 ng/ml.
9 . A method of providing a patient with a pre-determined dose of vanoxerine for use upon a future event of cardiac arrhythmia comprising: administering a first dose of vanoxerine to the patient to treat a first episode of cardiac arrhythmia; measuring the physiological concentration of vanoxerine in the patient; modifying a second dose of vanoxerine; and instructing the patient to self-administer the second dose of vanoxerine upon the occurrence of an episode of cardiac arrhythmia.
10 . The method of claim 10 wherein the physiological concentration is measured in the plasma.
11 . The method of claim 10 further comprising the step of comparing the measured dose of vanoxerine to a pre-determined target plasma level.
12 . The method of claim 11 wherein the target plasma level is between 20 and 150 ng/ml.
13 . The method of claim 11 wherein the target plasma level is between 60 and 130 ng/ml.
14 . A method of treating a patient comprising:
a. identifying a patient experiencing an episode of cardiac arrhythmia;
b. administering vanoxerine to said patient thereby treating the episode of cardiac arrhythmia;
c. prescribing a second course of vanoxerine to treat a second, subsequent episode of cardiac arrhythmia; and
d. instructing the patient to self-administer the second course of vanoxerine upon the occurrence of a second episode of cardiac arrhythmia.
15 . The method of claim 14 further comprising the step of measuring the patients pharmacokinetic response to vanoxerine after the administration of the first dose of vanoxerine.
16 . The method of claim 14 , wherein the pharmacokinetic response is measured in the plasma of the patient.
17 . The method of claim 16 , further comprising the step of comparing the plasma level of the patient to a pre-determined effective plasma concentration.
18 . The method of claim 17 wherein the pre-determined effective plasma concentration is between 20 and 150 ng/ml.
19 . The method of claim 17 wherein the pre-determined effective plasma concentration is between 60 and 130 ng/ml.
20 . The method of claim 17 wherein the pre-determined effective plasma concentration is at least 60 ng/ml.